Andrulis Pharmaceuticals Corp.

Other

Peter J Andrulis, Jr

Murray W Drulak

Isaac A Angres

Devinder S Gill

A method is provided for the treatment of neoplastic diseases in a mammal which comprises administering to said mammal a therapeutically effective amount of thalidomide. The method also uses a combination of thalidomide with other anti-neoplastic agents. Additionally, pharmaceutical compositions containing thalidomide and other anti-cancer agents are also provided.

Treatment of cancer with thalidomide alone or in combination with other

A pharmaceutical composition comprising: (a) a tumor necrosis factor inhibitor; (b) a compound selected from the group consisting of reverse transcriptase inhibitors, protease inhibitor, a gene inhibitor, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines, and (c) a pharmaceutical inert nontoxic carrier are described.

Use of tumor factor inhibitors together with antiviral agents and

A method for treatment of malignant melanoma by administering an effective amount of thalidomide alone or in combination with other anti-melanoma drugs.

Treatment of melanomas with thalidomide alone or in combination with

Methods of treatment for inflammatory and autoimmune dermatoses which comprises topical and/or systemic administration of a therapeutically-effective amount of thalidomide alone or in combination with other dermatological agents.

Treatment of inflammatory and/or autoimmune dermatoses with thalidomide

In accordance with the present invention, a method is provided for treating reperfusion injury, ischemia and runaway inflammatory conditions with thalidomide alone or in combination with other drugs selected from the group consisting of nitrates, beta-adrenoceptor blocking agents, anti-platelet/thrombolytic drugs, drugs acting as the arachindonic acid cascade and calcium antagonists. Pharmaceutical compositions comprising thalidomide alone or in combination with other drugs are also provided.

Treatment of ischemia/reperfusion injury with thalidomide alone or in

A method for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state.

Method for treating neurocognitive disorders

A method for treating insulin-resistant diabetes in mammals which comprises administering to said afflicted animals a prophylactically or therapeutically effective amount of thalidomide.

Treatment of insulin resistant diabetes with thalidomine

Platinum(amine) complexes, when covalently linked to a water-soluble, biodegradable or biostable polymer, exhibit high antitumor activity at low dosages of platinum against L1210 and solid tumors. The complexes are platinum square planar complexes and octahedral structures of the formulae ##STR1## wherein A.sub.2 represents either 2 ammonia ligands, 2 monodentate amine ligands or a single bidentate amine ligand; P is either a biodegradable or a biostable but biocompatible polymer having pendent anionic groups which form covalent linkages with Pt; o is a positive integer and X is an anionic ligand.

Growing community of inventors

Bethesda, MD, United States of America

Peter J Andrulis, Jr